Shattuck Labs, Inc.
STTKHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeShattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company carries a $456.2M market cap, placing it firmly in the small-cap category. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study.
Market Cap
$456.2M
Beta
1.19
P/E (TTM)
—
P/E (Fwd)
-11.63
EPS (TTM)
$-0.56
EPS (Fwd)
$-0.51
ROE
-61.0%
ROA
-36.7%
Cash
$90.4M
Total Debt
$2.9M
Free CF
-$22.4M
52W Change
469.4%
Annual Financials
Cash vs Debt
With $90.4M in cash and $2.9M in debt, STTK maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$22.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -61.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $652K (2022) to $1.0M (2025), reflecting a 53% increase over the period.
With cash comfortably exceeding debt, STTK has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Shattuck Labs, Inc. and its sector.